Company intelligence / Profile preview
TWi Biotechnology, Inc.
- Ownership
- Private
- Development stage
- Phase 2
Overview
TWi Biotechnology is a clinical-stage biopharmaceutical company focused on developing repositioned small molecule drugs for rare diseases associated with inflammation. Its lead asset, diacerein (AC‑203), is in global Phase III trials for epidermolysis bullosa. Other programs include topical tofacitinib citrate for granuloma annulare and vitiligo in early clinical development. The company has demonstrated positive safety and efficacy signals in rare dermatological indications.
- Therapeutic areas
- DermatologyRheumatologyEndocrinology
- Modalities
- Small molecules (notably diacerein and tofacitinib citrate)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on TWi Biotechnology, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TWi Biotechnology, Inc..